Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P
Contemp Clin Trials. 2025; 150:107816.
PMID: 39842691
PMC: 11867840.
DOI: 10.1016/j.cct.2025.107816.
Bart G, Barth K, Baukol P, Enns E, Ghitza U, Harris J
Addict Sci Clin Pract. 2024; 19(1):91.
PMID: 39623502
PMC: 11610182.
DOI: 10.1186/s13722-024-00510-5.
Miller M, Carpenter R, Nance M, Freeman L, Metrik J, Borsari B
Alcohol Clin Exp Res (Hoboken). 2024; 48(11):2126-2136.
PMID: 39466174
PMC: 11622692.
DOI: 10.1111/acer.15436.
Hurzeler T, Logge W, Watt J, DeMayo M, Suraev A, McGregor I
Contemp Clin Trials Commun. 2024; 41:101341.
PMID: 39252861
PMC: 11382041.
DOI: 10.1016/j.conctc.2024.101341.
Grodin E, Baskerville W, Meredith L, Nieto S, Ray L
Alcohol Alcohol. 2024; 59(3).
PMID: 38725398
PMC: 11082523.
DOI: 10.1093/alcalc/agae032.
Course of avoidant/restrictive food intake disorder: Emergence of overvaluation of shape/weight.
Kambanis P, Mancuso C, Becker K, Eddy K, Thomas J, De Young K
J Eat Disord. 2024; 12(1):54.
PMID: 38702736
PMC: 11067077.
DOI: 10.1186/s40337-024-01001-3.
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P
Contemp Clin Trials. 2024; 142:107543.
PMID: 38657730
PMC: 11180567.
DOI: 10.1016/j.cct.2024.107543.
A randomized clinical trial to assess feasibility, acceptability and preliminary effects of telehealth-delivered cognitive-behavioral therapy for perceived social isolation among individuals with opioid use disorders.
Ashrafioun L, Allan N, Stecker T
Drug Alcohol Depend. 2024; 258:111268.
PMID: 38520791
PMC: 11088495.
DOI: 10.1016/j.drugalcdep.2024.111268.
Depressive and Anxiety Symptoms Predict Obsessive and Compulsive Cravings among Depressed Alcoholics.
Miller M, Cornelius J, Kirisci L, Douaihy A, Salloum I
Addict Disord Their Treat. 2024; 19(4):228-233.
PMID: 38516416
PMC: 10956405.
DOI: 10.1097/adt.0000000000000202.
Increased Intestinal Permeability and Decreased Resiliency of the Intestinal Barrier in Alcoholic Liver Disease.
Swanson G, Garg K, Shaikh M, Keshavarzian A
Clin Transl Gastroenterol. 2024; 15(4):e00689.
PMID: 38334953
PMC: 11042778.
DOI: 10.14309/ctg.0000000000000689.
The connection still matters: Therapeutic alliance with digital treatment for alcohol use disorder.
Benitez B, Frankforter T, Nich C, Kiluk B
Alcohol Clin Exp Res (Hoboken). 2024; 47(11):2197-2207.
PMID: 38226756
PMC: 10792249.
DOI: 10.1111/acer.15199.
Chronic Pain and Cannabis Use Frequency, Intensity, and Severity in Young Adults.
Hayaki J, Abrantes A, Anderson B, Stein M
Subst Use Misuse. 2023; 59(4):576-582.
PMID: 38017655
PMC: 10922830.
DOI: 10.1080/10826084.2023.2287240.
Temporal associations linking alcohol and cannabis use to cigarette smoking in young adults engaged in a tobacco cessation and relapse monitoring study.
Walters K, Emery N, Thrul J, Tomko R, Gray K, McClure E
Addict Behav. 2023; 149:107902.
PMID: 37924584
PMC: 10842007.
DOI: 10.1016/j.addbeh.2023.107902.
Data driven mixed effects modeling of the dual process framework of addiction among individuals with alcohol use disorder.
Everett R, Lewis A, Kuerbis A, Peace A, Li J, Morgenstern J
PLoS One. 2023; 18(8):e0265168.
PMID: 37549160
PMC: 10406226.
DOI: 10.1371/journal.pone.0265168.
Monitoring Cigarette Smoking and Relapse in Young Adults With and Without Remote Biochemical Verification: Randomized Brief Cessation Study.
McClure E, Baker N, Walters K, Tomko R, Carpenter M, Bradley E
JMIR Form Res. 2023; 7:e47662.
PMID: 37498643
PMC: 10415950.
DOI: 10.2196/47662.
Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.
Yammine L, Verrico C, Versace F, Webber H, Suchting R, Weaver M
BMJ Open. 2023; 13(6):e072707.
PMID: 37316311
PMC: 10277057.
DOI: 10.1136/bmjopen-2023-072707.
Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study.
Sagar K, Dahlgren M, Smith R, Lambros A, Gruber S
Cannabis. 2023; 4(2):47-59.
PMID: 37287530
PMC: 10212242.
DOI: 10.26828/cannabis/2021.02.004.
Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial.
McCormack R, Rotrosen J, Gauthier P, DOnofrio G, Fiellin D, Marsch L
Ann Emerg Med. 2023; 82(3):272-287.
PMID: 37140493
PMC: 10524047.
DOI: 10.1016/j.annemergmed.2023.02.013.
CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure.
Lambros A, Sagar K, Dahlgren M, Kosereisoglu D, El-Abboud C, Smith R
Sci Rep. 2023; 13(1):5869.
PMID: 37041309
PMC: 10090150.
DOI: 10.1038/s41598-023-32671-9.
Age as a moderator of motivational interviewing and nondirective client-centered psychotherapy for alcohol use disorder: An exploratory study.
Kuerbis A, Behrendt S, Morgenstern J
Alcohol Clin Exp Res (Hoboken). 2023; 47(3):527-539.
PMID: 36871206
PMC: 10050112.
DOI: 10.1111/acer.15015.
